Skip to main content

Table 1 Dose objectives for a single HDR brachytherapy treatment

From: The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

Structure

Dose parameter1

Objective (Acceptable)

Prostate

V 90%

Greater than 99% (95%).

V 100%

Greater than 95% (90%).

V 150%

Less than 35% (40%).

V 200%

Less than 11% (15%).

CTVp2

V 90%

Greater than 99% (95%).

V 100%

Greater than 95% (90%).

Urethra

D 0.01 mL

Less than 12 Gy.

Rectum

D 0.1 mL

Less than 8.5 Gy (9 Gy).

D 1 mL

Less than 6.5 Gy (7 Gy).

  1. 1 The dose parameter “V X%” refers to the proportion of the structure’s volume receiving at least X% of the prescription dose. The dose parameter “D Y mL” refers to the dose received by the hottest Y mL of the structure.
  2. 2 The clinical target volume of the primary tumor (CTVp) is constructed by taking the union of the GTVs, as delineated on MR and PSMA PET, expanding the structure by 5 mm uniformly, then editing the resulting structure to the boundary of the prostate and the urethra.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us